ANL 28.45 Decreased By ▼ -1.10 (-3.72%)
ASC 19.69 Decreased By ▼ -0.29 (-1.45%)
ASL 24.45 Increased By ▲ 0.05 (0.2%)
BOP 8.17 Decreased By ▼ -0.09 (-1.09%)
BYCO 9.80 Decreased By ▼ -0.24 (-2.39%)
FCCL 21.88 Decreased By ▼ -0.07 (-0.32%)
FFBL 26.60 Decreased By ▼ -0.40 (-1.48%)
FFL 20.05 Increased By ▲ 0.72 (3.72%)
FNEL 8.39 Decreased By ▼ -0.03 (-0.36%)
GGGL 24.90 Decreased By ▼ -0.26 (-1.03%)
GGL 41.69 Decreased By ▼ -1.91 (-4.38%)
HUMNL 6.81 Decreased By ▼ -0.11 (-1.59%)
JSCL 20.60 Decreased By ▼ -0.90 (-4.19%)
KAPCO 39.00 No Change ▼ 0.00 (0%)
KEL 3.82 Decreased By ▼ -0.01 (-0.26%)
MDTL 3.39 Decreased By ▼ -0.13 (-3.69%)
MLCF 43.05 Decreased By ▼ -0.45 (-1.03%)
NETSOL 149.30 Decreased By ▼ -7.70 (-4.9%)
PACE 7.12 Decreased By ▼ -0.08 (-1.11%)
PAEL 32.05 Decreased By ▼ -1.23 (-3.7%)
PIBTL 10.86 Decreased By ▼ -0.09 (-0.82%)
POWER 8.95 Decreased By ▼ -0.11 (-1.21%)
PRL 22.80 Decreased By ▼ -0.30 (-1.3%)
PTC 11.66 Decreased By ▼ -0.22 (-1.85%)
SILK 1.77 Increased By ▲ 0.05 (2.91%)
SNGP 49.70 Decreased By ▼ -1.04 (-2.05%)
TELE 15.50 Increased By ▲ 0.33 (2.18%)
TRG 154.43 Decreased By ▼ -5.82 (-3.63%)
UNITY 40.00 Decreased By ▼ -0.55 (-1.36%)
WTL 3.47 Increased By ▲ 0.04 (1.17%)
BR100 5,043 Decreased By ▼ -50.24 (-0.99%)
BR30 25,215 Decreased By ▼ -494.66 (-1.92%)
KSE100 47,055 Decreased By ▼ -257.04 (-0.54%)
KSE30 18,837 Decreased By ▼ -126.39 (-0.67%)

Coronavirus
VERY HIGH Source: covid.gov.pk
Pakistan Deaths
23,360
6524hr
Pakistan Cases
1,029,811
4,95024hr
8.46% positivity
Sindh
380,093
Punjab
356,211
Balochistan
30,289
Islamabad
87,304
KPK
143,673
World

AstraZeneca hits snag in Covid drug development

  • Vaccine-maker says main goal to treat Covid-19 symptoms in exposed patients has failed
15 Jun 2021

LONDON: Covid vaccine-maker AstraZeneca on Tuesday revealed it had hit a setback in trials of a treatment for the coronavirus.

The drug, made from a combination of two antibodies, failed its main goal to treat Covid-19 symptoms in exposed patients, AstraZeneca said in a statement.

The treatment has been undergoing phase 3 or final clinical trials to assess its safety and efficacy.

AstraZeneca said that 1,121 unvaccinated adults had been exposed to an infected person as part of the trial.

Treatment AZD7442 reduced the risk of developing symptoms by only 33 percent -- which was "not statistically significant", it added.

The company is nevertheless continuing trials to assess whether the drug can prevent Covid or treat more severe symptoms.

The US government has funded the development of AZD7442 and has agreements to receive 700,000 doses.

Meanwhile, AstraZeneca's Covid vaccine, which was developed with the University of Oxford, continues to face safety doubts.

The jab has been suspended in several European countries over reports of rare blood clots.

A top official in the European Medicines Agency on Sunday suggested that it might be worth abandoning AstraZeneca's coronavirus vaccine for all age groups where alternatives are available.

However, a study from British health authorities showed on Monday that two doses of AstraZeneca/Oxford or rival Pfizer/BioNTech vaccines stopped the need for in-patient treatment in more than 90 percent of cases of the Delta variant.

The UK government on Monday announced a four-week delay to the full lifting of coronavirus restrictions in England due to a surge in infections caused by Delta, which first appeared in India.